Unpredictability reigned in a turbulent 2022. Yet Abbott weathered the storm, thanks to its diversified business portfolio and robust product pipeline. As 2023 kicks off, Abbott Chairman and CEO Robert Ford participated in the J.P. Morgan Healthcare Conference and shared insight on the company's new product pipeline, the FreeStyle Libre portfolio and COVID-19 testing. Here are key highlights from the presentation: The company's new product pipeline is a strong balance of iterative and transformative opportunities, including: Aveir single-chamber VR pacemaker system, treating slower-than-normal heart rhythms Navitor transcatheter aortic valve implantation system, treating aortic stenosis TriClip transcatheter edge-to-edge repair device, for tricuspid valve regurgitation And U.S. expanded indication of CardioMEMS, for remote heart failure monitoring Abbott has a strong portfolio of tests for respiratory viruses that are currently circulating. The company makes diagnostic tests that detect RSV, influenza and COVID-19 that can be used in various settings, including hospitals, urgent care centers, pediatric offices and retail pharmacies. There are a number of growth and innovation opportunities on the horizon for Abbott's FreeStyle Libre portfolio, including: The Centers for Medicare and Medicaid Services' proposal to make continuous glucose monitors more accessible for Medicare patients,1 which would broaden coverage to all insulin users if finalized as proposed2 Authorizing the pairing of the FreeStyle Libre portfolio with automated insulin dosing systems (Not available in the U.S.) A first-of-its-kind dual monitoring glucose and ketone sensor — currently in development Abbott's new category of consumer biowearables, called Lingo, is expected to launch in Europe later this year, enabling the company to broaden the reach and impact of its biosensor technology beyond people with diabetes.3 The COVID-19 testing market has largely transitioned to rapid tests, where Abbott is the leader. New variants are driving an increase in COVID-19 cases around the world, leading to continued demand for rapid tests. Rapid tests, like Abbott’s BinaxNOW and Panbio tests,4 are a quick and easy way for people to know if they have COVID-19, enabling them to take steps to help prevent spreading the virus if they test positive. For more information, listen to Mr. Ford's presentation at the conference. References 1 Centers for Medicare and Medicare Proposed Local Coverage Determination DL3382, https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39473&ver=16 2 Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors. 3 The Lingo portfolio of products are under development and are not intended for medical use. They are not intended for use in screening, diagnosis, treatment, cure, mitigation, prevention, or monitoring of diseases. Lingo products are not for sale in the U.S. 4 The Panbio COVID-19 test is not available in all countries. Not approved for sale in the USA.